Kidney-derived cells and methods of use in tissue repair and regeneration

• US 10,413,571 B2
• Filed: 08/17/2016
• Issued: 09/17/2019
• Est. Priority Date: 10/12/2006
• Status: Active Grant

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Inventors: Colter, David C., Seyda, Agnieszka, Buensuceso, Charito S., Gosiewska, Anna
• Primary Examiner(s): Ton, Thaian N
• Assistant Examiner(s): Montanari, David A.
• Application Number:
  US15/238,993
• Publication Number:
  US 20160375062A1
• Time in Patent Office: 1,126 Days
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2533/40 Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
• CPC Class Codes: C12N 5/0686 Kidney cells
• CPC Class Codes: C12N 5/0687 Renal stem cells; Renal progenitors

Abstract

Isolated or purified mammalian kidney-derived cell populations from mammalian kidney tissue are provided. Methods are provided for the isolation and purification of the mammalian kidney-derived cell population. Methods for treating kidney disease are provided by administration of the isolated or purified mammalian kidney-derived cell population to a mammalian subject.

Claims

1. A method for treating ischemic kidney disease in a human or an immunocompromised mouse comprising administering directly to the kidney a therapeutically effective amount of an isolated or purified human kidney-derived cell population,

wherein said cell population is capable of self-renewal and expansion in culture, wherein the cell population is positive for expression of HLA-I and CD44 and at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eya1, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, and GDF5, and negative for the expression of CD133, E-cadherin, and Wnt-4 and at least one of Sox2, FGF4, hTert, SIX2 and GATA-4, and

wherein said administration reduces or eliminates the ischemic kidney disease in the treated human or immunocompromised mouse.

2. The method of claim 1, wherein the administration of said cell population induces an effect selected from:

(a) formation of blood vessels supplying blood to the ischemic tissue;

(b) blood flow to the ischemic tissue;

(c) oxygen supply to the ischemic tissue; and

(d) combinations thereof.

3. The method of claim 1, wherein the administration of said cell population induces formation of kidney subcapsular region tissue, kidney cortex tissue, or kidney medulla tissue.

4. The method of claim 1, wherein the treating ischemic kidney disease is in a human.

5. The method of claim 1, wherein the human kidney-derived cell population is positive for expression of at least one of Eya1, WT1, FoxD1, BMP7, BMP2, GDF5, EpoR and Rex-1, and negative for expression of at least one of Sox2, FGF4, and hTert.

6. The method of claim 1, wherein the human kidney-derived cell population is positive for at least one of cell-surface markers, CD24, CD29, CD49c, CD73, CD90, CD166, and SSEA-4, and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD138, and CD141.

7. The method of claim 1, wherein the human kidney-derived cell population is positive for at least one of the surface markers CD166 and SSEA-4, and negative for at least one of the cell-surface markers HLA II, CD80, CD86, CD133, CD141 and E-cadherin.

8. The method of claim 1, wherein the human kidney-derived cell population is positive for the cell-surface marker HLA I, and negative for at least one of cell-surface markers HLA II, CD80, and CD86.

9. The method of claim 1, wherein the human kidney-derived cell population is non-immunogenic for allogeneic transplantation in a human subject.

10. The method of claim 1, wherein the human kidney-derived cell population is derived from kidney cortex, kidney medulla or kidney subcapsular region.

11. The method of claim 1, wherein the method comprises administering a pharmaceutical composition comprising the isolated or purified human kidney-derived cell population.